GSK, Agenus shingles vaccine meets primary endpoint

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said its HZ/su herpes zoster vaccine ( GSK1437173A) met the primary endpoint of reducing the risk of shingles by 97.2% in people aged 50 and older vs. placebo in the Phase III ZOE-50 study. The vaccine candidate contains the adjuvant QS-21 Stimulon from Agenus Inc. (NASDAQ:AGEN).

Agenus is eligible for royalties on sales of HZ/su under a 2006 deal giving GSK rights to the adjuvant. ...